Barclays raised the firm’s price target on Terns Pharmaceuticals (TERN) to $28 from $27 and keeps an Overweight rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Promising Outlook for Terns Pharmaceuticals: Buy Rating Backed by Strong Financials and Potential Breakthrough in Leukemia Treatment
- Terns Pharmaceuticals reports Q3 EPS (27c), consensus (30c)
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright